Header
For Healthcare Professionals

In the treatment of HF patients with LVEF >40%*

JARDIANCE protected the kidneys by slowing the decline of renal function over time†1

Included patients down to an eGFR of 20 mL/min/1.73 m2.1

02-components-media-desktop-image-zoom@3x

JARDIANCE is approved in India by DCGI for use in patients down to eGFR 30 mL/min/1.73 m2 only.

  1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%).1
  • †
    The rate of decline in eGFR was a prespecified secondary outcome of the EMPEROR-Preserved trial.1
  • ‡
    Mean baseline eGFR (CKD-EPI)EPI: JARDIANCE: 60.6 mL/min/1.73 m2; placebo: 60.6 mL/min/1.73 m2.1
  • §
    Background therapy: All appropriate treatments for heart failure or comorbid conditions could be initiated or altered at the discretion of the clinician.1
  • CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; eGFR=estimated glomerular filtration rate; HF=heart failure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SE=standard error of the mean.

In the treatment of HF patients with LVEF >40%*

JARDIANCE protected the kidneys by slowing the decline of renal function over time#1

Included patients down to an eGFR of 20 mL/min/1.73 m2.1

02-components-media-desktop-image-zoom

JARDIANCE is approved in India by DCGI for use in patients down to eGFR 30 mL/min/1.73 m2 only.

  1. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  2. Butler J, Zannad F, Filippatos G, Anker SD, Packer M. Ten lessons from the EMPEROR-Reduced trial. Eur J Heart Fail. 2020;22(11):1991-1993. doi:10.1002/ejhf.2009

  3. McDonagh TA, et al. Eur Heart J. 2021;42:3599.

  4. Packer M, et al. Circulation. 2021;143(4):326-336.

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%).1
  • †
    In the EMPEROR-Reduced trial, a randomised, double-blind, parallel group, placebo-controlled study of 3730 patients with HFrEF, the efficacy and safety of JARDIANCE 10 mg (n=1863) were evaluated vs placebo (n=1867). The primary endpoint in the EMPEROR-Reduced trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 25% RRR in this endpoint (HR=0.75; 95% CI: 0.65, 0.86; p<0.001).1
  • ‡
    ARR calculation: JARDIANCE number of patients with events 361/total number of patients 1863=19.4%; placebo number of patients with events 462/total number of patients 1867=24.7%; 24.7%-19.4%=5.3%.1,2
  • II
    The occurrence of all HHF, including first and recurrent events, was a prespecified secondary outcome of the EMPEROR-Reduced trial.1
  • In addition to the RRR of all HHF, including first and recurrent events, the risk of total hospitalisations of any reason was also significantly reduced (HR=0.85, 95% CI: 0.75, 0.95).1
  • §
    Standard of care: All patients received appropriate treatments for heart failure, including diuretics, inhibitors of the renin angiotensin system and neprilysin, beta blockers, mineralocorticoid receptor antagonists and, when indicated, cardiac devices.1
  • #
    The rate of decline in eGFR was a prespecified secondary outcome of the EMPEROR Reduced trial.1
  • **
    Mean baseline eGFR (CKD-EPI): JARDIANCE: 61.8 mL/min/1.73 m2; placebo: 62.2 mL/min/1.73 m2.1
  • ARNi=Angiotensin receptor neprilysin inhibitor; ARR=absolute risk reduction; CI=confidence interval; CKD EPI=Chronic Kidney Disease Epidemiology Collaboration; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; HFrEF=heart failure with reduced ejection fraction; HHF= hospitalisation for heart failure; HR=hazard ratio; LVEF=left ventricular ejection fraction; NNT=number needed to treat; NYHA=New York Heart Association; RRR=relative risk reduction.

In the treatment of HF patients with LVEF >40%*

JARDIANCE has a proven safety and tolerability profile2

Rates of hypoglycaemia§ were similar between JARDIANCE and placebo in patients with or without T2D.2

02-components-media-desktop-image-zoom@3x

In the treatment of HF patients with LVEF ≤40%II

JARDIANCE has a proven safety and tolerability profile3

Rates of hypoglycaemia§ were similar between JARDIANCE and placebo in patients with or without T2D.3

02-components-media-desktop-image-zoom

  1. JARDIANCE® prescribing information, version 20-Jan 2023. Boehringer Ingelheim India Pvt. Ltd.

  2. Anker SD, Butler J, Filippatos G, et al; EMPEROR Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  3. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%).2
  • †
    Safety analyses included all patients who had received at least 1 dose of empagliflozin or placebo. The 1 patient in the empagliflozin group who did not receive empagliflozin was excluded from the safety analyses.2
  • ‡
    Safety analyses included all patients who had received at least 1 dose of empagliflozin or placebo. The 2 patients in the placebo group who did not receive placebo were excluded from the safety analyses.2
  • §
    Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL (3.9 mmol/L) or that required assistance.2,3
  • II
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%).3
  • Safety analyses included all patients who had received at least 1 dose of empagliflozin or placebo. Patients who received at least 1 dose of empagliflozin or placebo were included in the safety analyses. There were 4 patients excluded from the safety analyses who did not receive placebo.3
  • AE=adverse event; HF=heart failure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; T2D=type 2 diabetes.

In non T2D patients with HF,

JARDIANCE® showed no additional safety concerns1,2

02-components-media-desktop-image-zoom@3x
02-components-media-desktop-image-zoom@3x

  1. Packer M, et al. N Engl J Med. 2020;383(15):1413-1424.

  2. Anker SD, et al. N Engl J Med. 2021;385(16):1451-1461.

  • *
    Percentages calculated using total number of patients per treatment as the denominator.
  • HF=heart failure; T2D=type 2 diabetes; CV=cardiovascular; HHF=hospitalisation for heart failure; HR=hazard ratio;
  • CI=confidence interval; LVEF=left ventricular ejection fraction; HFrEF=heart failure with reduced ejection fraction;
  • HFpEF=heart failure with preserved ejection fraction.

PC-IN-103696 Validity till July 2025